tak 779 has been researched along with enfuvirtide in 10 studies
| Studies (tak 779) | Trials (tak 779) | Recent Studies (post-2010) (tak 779) | Studies (enfuvirtide) | Trials (enfuvirtide) | Recent Studies (post-2010) (enfuvirtide) |
|---|---|---|---|---|---|
| 118 | 1 | 35 | 718 | 89 | 154 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (80.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CH; Ho, P; Huang, L; Lai, W; Li, Z; Montefiori, D | 1 |
| Ballweber, L; Fialkow, M; Hladik, F; Kreger, A; Lentz, G; McElrath, MJ; Robinson, B; Sakchalathorn, P; Terker, A | 1 |
| Ahmad, N; Blumenthal, R; Derdeyn, CA; Doms, RW; Gallo, SA; Harvey, PE; Hunter, E; Miamidian, JL; Pohlmann, S; Reeves, JD; Sfakianos, JN; Sharron, M | 1 |
| Maddon, PJ; Olson, WC | 1 |
| Ahmad, N; Biscone, MJ; Doms, RW; Lee, FH; Miamidian, JL; Pierson, TC; Reeves, JD | 1 |
| Durnin, JP; Kabat, D; Platt, EJ | 1 |
| Kabat, D; Platt, EJ; Rose, PP; Shea, DM | 1 |
| Albert, J; Esbjörnsson, J; Fenyö, EM; Jansson, M; Karlsson, A; Medstrand, P; Öberg, M; Repits, J | 1 |
| Gantlett, KE; Sattentau, QJ; Weber, JN | 1 |
| Antunes, F; Barroso, H; Bártolo, I; Borrego, P; Caixas, U; Calado, R; Cavaco-Silva, P; Doroana, M; Maltez, F; Marcelino, JM; Rocha, C; Taveira, N | 1 |
1 review(s) available for tak 779 and enfuvirtide
| Article | Year |
|---|---|
Resistance to HIV-1 entry inhibitors.
Topics: Amides; Anti-HIV Agents; Benzylamines; CD4 Immunoadhesins; Cyclams; Drug Resistance, Viral; Enfuvirtide; Heterocyclic Compounds; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Peptide Fragments; Piperazines; Quaternary Ammonium Compounds | 2003 |
9 other study(ies) available for tak 779 and enfuvirtide
| Article | Year |
|---|---|
Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.
Topics: Animals; Anti-HIV Agents; Betulinic Acid; Cell Line; Chlorocebus aethiops; COS Cells; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV-1; Humans; Membrane Fusion; Microbial Sensitivity Tests; Models, Molecular; Pentacyclic Triterpenes; Peptide Fragments; Triterpenes | 2008 |
Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells.
Topics: Adult; Anti-HIV Agents; Benzothiepins; Cells, Cultured; Enfuvirtide; Female; Flow Cytometry; Genotype; HIV Envelope Protein gp41; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; In Vitro Techniques; Microscopy, Confocal; Peptide Fragments; Polymerase Chain Reaction; Virus Integration | 2010 |
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Topics: 3T3 Cells; Amides; Amino Acid Substitution; Animals; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Antigens; Drug Resistance, Viral; Enfuvirtide; Genes, env; HeLa Cells; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV-1; Humans; Kinetics; Membrane Fusion; Mice; Peptide Fragments; Protein Binding; Protein Conformation; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, CXCR4; Recombinant Fusion Proteins | 2002 |
Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.
Topics: Amides; Anti-HIV Agents; Binding Sites; CD4 Antigens; Cell Line; Enfuvirtide; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV-1; Humans; Membrane Fusion; Mutation; Peptide Fragments; Quaternary Ammonium Compounds; Receptors, CCR5; Structure-Activity Relationship | 2004 |
Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
Topics: Amides; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Antigens; Enfuvirtide; HeLa Cells; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV-1; Humans; Kinetics; Peptide Fragments; Protein Conformation; Quaternary Ammonium Compounds; Receptors, CCR5; Virus Replication | 2005 |
Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan.
Topics: Adaptation, Biological; Amides; Amino Acid Substitution; Cell Line; Cloning, Molecular; DNA Mutational Analysis; Enfuvirtide; HeLa Cells; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV-1; Humans; Models, Molecular; Mutation; Peptide Fragments; Polysaccharides; Quaternary Ammonium Compounds; Receptors, CCR5; Virus Replication | 2005 |
Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency.
Topics: Acquired Immunodeficiency Syndrome; Amides; CCR5 Receptor Antagonists; Chemokine CCL5; Enfuvirtide; HIV Envelope Protein gp41; HIV-1; Humans; Molecular Sequence Data; Peptide Fragments; Quaternary Ammonium Compounds; Virus Replication | 2005 |
Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides.
Topics: Amides; Anti-HIV Agents; Cell Line; Dextran Sulfate; Drug Combinations; Drug Synergism; Enfuvirtide; HIV Antibodies; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV-1; Humans; Leukocytes, Mononuclear; Naphthalenesulfonates; Peptide Fragments; Polyelectrolytes; Polymers; Quaternary Ammonium Compounds | 2007 |
Baseline susceptibility of primary HIV-2 to entry inhibitors.
Topics: Amides; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; HIV-2; Humans; Inhibitory Concentration 50; Male; Maraviroc; Microbial Sensitivity Tests; Peptide Fragments; Quaternary Ammonium Compounds; Triazoles | 2012 |